{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > PI3K/Akt/mTOR > AlpelisibCAS：1217486-61-7
Molecular Formula：C19H22F3N5O2S
Molecular Weight：441.47
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：White to yellow Solid
Qty：
Size：
| CAS | 1217486-61-7 |
| Name | Alpelisib |
| Molecular Formula | C19H22F3N5O2S |
| Molecular Weight | 441.47 |
| Solubility | Soluble in DMSO |
| Purity | ≥98% |
| Appearance | White to yellow Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| Delivery Time | 1-2 Days |
| MDL | MFCD22417085 |
| SMILES | CC(N=C(S1)NC(N2CCC[C@H]2C(N)=O)=O)=C1C3=CC(C(C)(C(F)(F)F)C)=NC=C3 |
| InChIKey | STUWGJZDJHPWGZ-LBPRGKRZSA-N |
| InChI | InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1 |
| PubChem CID | 56649450 |
| Target Point | PI3K |
| Passage | PI3K/Akt/mTOR |
| Background | Alpelisib is a potent and selective PI3Kα inhibitor. |
| Biological Activity | Alpelisib 是有效，选择性的 PI3Kα 抑制剂，IC50 为5 nM[1-5]。 |
| IC50 | p110α:5nM;p110γ:250nM;p110δ:290nM;p110β:1200nM [1-5] |
| Data Literature Source | [1]. Furet P，et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3741-8. [2]. Fritsch C，et al. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther. 2014 May;13(5):1117-29. [3]. Gobin B，et al. BYL719，a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. Int J Cancer. 2015 Feb 15;136(4):784-96. [4]. Venot Q，et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature. 2018 Jun;558(7711):540-546. [5]. Ding J，et al. Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3Kα inhibition through the transcriptional regulation of ERα. Cancer Lett. 2018 Oct 10;440-441:54-63. |
| Unit | Bottle |
| Specification | 1mg 5mg 10mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
